We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hill-Rom (HRC) Banks on Product Launches, Competition Rife
Read MoreHide Full Article
On Nov 7, we issued an updated research report on Batesville, IN-based Hill-Rom Holdings, Inc. . The company currently has a Zacks Rank #3 (Hold).
This leading global medical device companyexited fiscal 2017 on a strong note with fourth-quarter earnings and revenues beating the Zacks Consensus Estimate. The company saw a solid year-over-year increase in revenues on strong international growth. Hill-Rom is currently focused on gaining traction in the untapped international market on successful execution of the company’s strategy, courtesy of its efficient international team and organizational realignment. The company is focusing on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging. Moreover, an improvement in adjusted gross and operating margin buoys optimism.
In November 2017, Hill-Rom outlined impressive long-term growth strategies along with key initiatives. The company also stated its financial goals through fiscal 2020.
Hill-Rom’s merger and acquisition (M&A) pipeline continues to be robust. The company aggressively pursues acquisitions to accelerate growth in five key clinical focus areas viz. advancing patient mobility, wound care and prevention, surgical, safety and efficiency, clinical workflow solutions and respiratory help. Apart from Welch Allyn and Trumpf, several recent noteworthy acquisitions include Virtus and Aspen Surgical.
However, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.
Overall, for the last six months, Hill-Rom has been trading below the broader industry. The stock has gained 4.3%, compared to the industry's rally of 6.6%.
Key Picks
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 78.6% over the last year.
Luminexhas a long-term expected earnings growth rate of 16.3%. The stock has gained 1.9% in the last year.
Intuitive Surgical has a long-term expected earnings growth rate of 9.1%. The stock has gained 85.2% in the last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Hill-Rom (HRC) Banks on Product Launches, Competition Rife
On Nov 7, we issued an updated research report on Batesville, IN-based Hill-Rom Holdings, Inc. . The company currently has a Zacks Rank #3 (Hold).
This leading global medical device companyexited fiscal 2017 on a strong note with fourth-quarter earnings and revenues beating the Zacks Consensus Estimate. The company saw a solid year-over-year increase in revenues on strong international growth. Hill-Rom is currently focused on gaining traction in the untapped international market on successful execution of the company’s strategy, courtesy of its efficient international team and organizational realignment. The company is focusing on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging. Moreover, an improvement in adjusted gross and operating margin buoys optimism.
In November 2017, Hill-Rom outlined impressive long-term growth strategies along with key initiatives. The company also stated its financial goals through fiscal 2020.
Hill-Rom’s merger and acquisition (M&A) pipeline continues to be robust. The company aggressively pursues acquisitions to accelerate growth in five key clinical focus areas viz. advancing patient mobility, wound care and prevention, surgical, safety and efficiency, clinical workflow solutions and respiratory help. Apart from Welch Allyn and Trumpf, several recent noteworthy acquisitions include Virtus and Aspen Surgical.
However, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.
Overall, for the last six months, Hill-Rom has been trading below the broader industry. The stock has gained 4.3%, compared to the industry's rally of 6.6%.
Key Picks
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 78.6% over the last year.
Luminexhas a long-term expected earnings growth rate of 16.3%. The stock has gained 1.9% in the last year.
Intuitive Surgical has a long-term expected earnings growth rate of 9.1%. The stock has gained 85.2% in the last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>